PRME News and Press, First Trust Heitman Global Prime Real Estate ETF From 06/22/23

-- Collaboration combines Prime Medicine’s Prime Editing platform with Cimeio Therapeutics’ Shielded Cell and Immunotherapy Pairs™ (SCIP™) platform -- -- Aim to reduce toxicity of conditioning regimens and introduce new therapeutic options that can expand the...

2023-06-09 17:15:14 ET Gainers: PepGen  ( PEPG ) +5% . Caribou Biosciences ( CRBU ) +4% . MaxCyte ( MXCT ) +4% . Noodles & Company ( NDLS ) +3% . Applied Digital  ( APLD ) +3% . Losers: Couchbase ( BASE ...

2023-06-02 10:15:00 ET Cathie Wood didn't make a lot of moves on Thursday, but she certainly made them count. The CEO, co-founder, and ace stock picker for the Ark Investment family of exchange-traded funds (ETFs) loaded up on a market darling that sold off despite posting better-than-expec...

CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime ...

2023-05-26 09:45:00 ET Cathie Wood is always making moves. The CEO, co-founder, and rock-star stock picker for the Ark Investment family of exchange-traded funds (ETFs) publishes her transactions at the end of every trading day. What's she buying these days? The growth-stock investor ad...

CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime ...

Data demonstrated Prime Editors efficiently, reproducibly and durably corrected the causative mutation of CGD, supporting advancement of development candidate PM359 New preclinical data highlighted ability of PASSIGE™ platform to generate multiplex-edited CAR-T cells without usin...

2023-05-11 11:54:36 ET Prime Medicine press release ( NASDAQ: PRME ): Q1 GAAP EPS of -$0.44 in-line. Cash and cash equivalents as of March 31, 2023 were $59.3 million. The Company expects that its existing cash and cash equivalents will be sufficient to fund its current op...

-- New data further demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting potential of PASSIGE platform to multiplex edit CAR-T cells to be presented at ASGCT Annual Meeting -- -- Expanded Board of Directors with appointment of Jeff Marrazzo, forme...

2023-04-23 09:10:30 ET Summary Proof of concept in vivo data from rodent studies and large animal studies for its technology is expected in the 2nd half of 2023. First IND application of PM359 treating patients with chronic granulomatous disease is expected in 2024. Additional...